Cite
HARVARD Citation
Geller, J. et al. (2020). ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. Cancer. 126 (24), pp. 5303-5310. [Online].